Anti-Human CD71 [Clone OKT-9] — Purifiedin vivoGOLD™ Functional Grade,Leinco,C2531

Host

Mouse

Reactivity

Human

Application

FC,IF,IHC,IP,WB

Platform ID

BAB759954110

Leinco

Headquarters

410 Axminister Drive St. Louis, Missouri 63026

Contact

Tel: +1 (800) 538-1145,+1 (636) 230-9477
Fax:

Product Specifications
Scientific Background

Specifications

NameAnti-Human CD71 [Clone OKT-9] — Purifiedin vivoGOLD™ Functional Grade
Cat. No.C2531
HostMouse
ReactivityHuman
ApplicationFC,IF,IHC,IP,WB
Clone NumberOKT-9
Concentration≥ 5.0 mg/ml
ImmunogenHuman acute lymphocytic leukemia cells
Purity>95% monomer by analytical SEC ⋅ >95% by SDS Page
Endotoxin Level< 1.0 EU/mg as determined by the LAL method
Shipping2 – 8° C Wet Ice
FormulationThis monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
StorageFunctional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Scientific Background

CD71 is a transferrin receptor that mediates cellular proliferation by promoting iron uptake 1,2 . Iron uptake occurs when diferric transferrin binds to CD71 at the cell surface, the transferrin-iron complex is internalized by endocytic vesicles, and the diferric iron is released into the cytoplasm 1,3,4 . CD71 is highly expressed on malignant cells, as iron uptake is necessary for aberrant cell proliferation 5 . Additionally, CD71 is involved in the pathogenesis of clade B New World mammarenaviruses (NWM), which cause the South American hemorrhagic fevers 6 . NWM viruses share a binding site on the apical domain of CD71, and blockade of this site is a research target for producing a broadly neutralizing immunotherapy. OKT-9 was generated by immunizing CAF 1 mice with human T cell leukemia cells (acute lymphoblastic leukemia, T-ALL cells) from donor patients 7,8 . Hybridomas were produced by fusing the resulting splenocytes with P3X63Ag8U1 myeloma cells and screening by indirect immunofluorescence. OKT-9 reactivity was shown to correlate with proliferation status in both normal and malignant cell populations 8 . OKT-9 has been found to target the same apical domain of CD71 as NWM viruses and can sterically block cellular entry of clade B NWM viral particles by blocking the GP1-CD71 interaction 6 . This in turn reduces cellular infection and presents an opportunity for the development of an immunotherapeutic agent capable of broad viral neutralization.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.